Taysha Gene Therapies Inc To Discuss CLN7 Program Acquisition Call Transcript
Good morning, and welcome to Taysha CLN7 Program webcast. Today, we will discuss the recent exclusive option to license from UT Southwestern worldwide rights to a clinical-stage AAV9 gene therapy program for the treatment of CLN7 program -- disease, provide an overview of CLN7 disease as well as research collaboration with UT Southwestern to develop a next-generation construct for CLN7 and a grant to Batten Hope to support patient awareness, disease education and newborn screening initiatives.
We will also review the patient natural history data and discuss the CLN7 program and our clinical development strategy. Joining me on today's call are R. A. Session, II, Taysha's President, CEO and Founder; and Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; as well as Dr. Steven Gray, Chief Scientific Adviser at Taysha and Associate Professor in the Department of Pediatrics at UT Southwestern and Dr. Angela Schulz, our key opinion leader guest speaker from Children's Hospital University Medical Center
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |